Spyre Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone. I hope everyone is having a great conference. Day two of our London Healthcare Conference. It has been really great to see the attendance, and I hope everyone is having a good set of meetings. My name is Akash Tewari. I head our pharma and biotech research efforts internally within Jefferies, and we have Cameron from Spyre, and one of our top picks in biotech. Cameron, why do I hand it off to you for some intro remarks, and we will get started?
Sure. Thanks for having me. Always an amazing conference. Broadly, our goal at Spyre is to create a set of products that raise the bar in autoimmune disease, really by taking what we think are the best mechanisms in known diseases, creating improved versions of the antibodies against those targets, and then combining them together in what we believe are elegant co-formulated products that can be delivered on a convenient basis. We started in inflammatory bowel disease. We think we have three of the best monotherapies in this space, and we are enrolling a large study now to evaluate the pairwise combinations of each of them, which we think have the potential to be much better than today's standard of care in IBD. More recently, we have expanded our efforts in HS.
This is an area like IBD, high unmet need, irreversible consequences of uncontrolled disease, and I think it is increasingly clear that TL1A and IL-17 are two of the best mechanisms in HS. We have long-acting optimized versions of both that we will be developing as monotherapies and/or combinations, again, with the idea that we can do better than the today's standard of care.
Understood. We will talk about combination approaches, and you have phase II data sets coming up. This was similar to some of the times the discussion we had with Apogee. When you think about long-acting therapies and what they provide from a health economic perspective, I feel like people think, "Well, it is a known target. This is not some high science approach." But adherence has a material impact on how payers view classes, what actual adoption ends up being, and I do not feel like it is appreciated enough. I think people are growing more aware of that in some of the conditions that Apogee went for, but I do not know if they necessarily appreciate that yet in UC and Crohn's, where, again, you actually have even more severe disease progression in some instances.
Can you talk about what you are providing for patients and payers that is unique beyond just good targets?
Yeah. I think ultimately our goal as an industry is to create products that improve the lives of patients. Nothing too complicated here. In IBD, it is a disease that every point of efficacy matters a lot. This is a disease that if it is uncontrolled, you can have resections, surgeries, fibrosis, stenosis. We have seen over the course of the last few decades, as drugs come out that are even, I think, modestly improvements over the existing standard of care, they have largely moved to those products even as the first generation went biosimilar. So we originally had HUMIRA, STELARA, and then we saw head-to-head victories by ENTYVIO, TREMFYA, SKYRIZI, and those drugs have really taken the lion's share of the market with changes in efficacy on the order of 8 to 12 points, around 10 points of remission, even without improvements in convenience.
I think what these combinations have the potential to do is deliver that level of improvement, maybe even more, while moving from drugs that are delivered every couple of weeks or intravenously to being able to be delivered four times a year as auto-injectors, which I think is really a major step forward. I think very likely to improve adherence, compliance, and really reduce the downstream consequences and costs of disease that, as I mentioned, are extraordinarily costly. So I think this is a better product for patients, it is a better product for payers, and ultimately, I think they should be highly valuable and used broadly.
Understood. I think a part of that is your team seems to be adamant that this really is a frontline drug opportunity. I think if you tell that to someone who maybe was not familiar with your regimens, they will always be like, "Oh, come on. There are biosimilars out there. There is HUMIRA out there. Why would anyone be using a brand of therapy in a frontline setting?" Can you talk about why you are confident that really the combination approach you are delivering is actually optimally a frontline regimen? Do you feel like that is increasingly recognized when you think about external discussions?
Yeah. I think over the last, it is over a decade now that the IBD field has moved towards top-down therapy. This really comes on the back of the PROFILE study, which is the most important clinical study, but I think it reflects on a great deal of evidence before that. The PROFILE study showed that using the best drug first leads to better long-term outcomes by a meaningful margin. They did not just show that in terms of patient outcomes, clinical outcomes. They also showed that it was cost-effective too, reducing surgeries, reducing hospitalizations. Again, to make this argument to the payers, these somewhat apparently could be minor improvements in efficacy matter a lot and lead to better products and better cost-effectiveness.
I think as we look forward, even as those first-generation drugs went biosimilar and go to a meaningfully different price point, that did not slow the growth of ENTYVIO, TREMFYA, SKYRIZI. I think in the next generation here, again, I think we can come out with products that beat those by a similar or greater margin, frankly, and be launching at the same time those drugs are still branded. I think we can be launching combinations at a more similar price point, actually, as those existing branded drugs, beat them by a clinically meaningful amount on efficacy, and I think those drugs will end up taking the lion's share. I say we see data more and more in IBD, even saw it just a few weeks ago from AbbVie's combination, that the separation that we see early in these patients tends to widen over time.
Again, pointing to you want to get people on the most effective drug as soon as you can, and you want to keep them there to avoid the consequences of this disease.
Understood. Last question again, in terms of where the products you have can really fit. One of the things we have noticed about J&J and their oral IL-23, which is a beautiful drug, they are running mild studies. So you are seeing appetite with oral biologic-like drugs, not just to be in the moderate to severe population, but really, and probably at even a lower cost, go for a mild, truly naive segment of patients. I think that is getting increasingly understood with oral, but I do not feel like it is talked enough about with long-acting injectables. How much has your team thought about that in terms of it being a market opportunity? Do you have maybe downstream plans to actually run studies in that population?
Given the safety profile, let's say even for the ENTYVIO or IL-23, where do you think biologic adoption could be in that population, which I don't think investors really model at all right now?
Yeah, I think in IBD, we're quite a ways away from complete penetration of advanced therapies. In ulcerative colitis, we're still below 50% in terms of the population receiving advanced therapies. In Crohn's, we're doing better. We're more like two-thirds of the population receiving advanced therapies there. But those numbers are going up as we learn more that you want to be on effective therapies early. I think oral therapies can be a helpful tool to actually get those numbers higher. That said, in IBD, there hasn't been a case where convenience alone is good enough, or you'd be willing to sacrifice safety or efficacy in exchange for convenience. I think in IBD, it is safety and efficacy first by quite a margin, and then if they're the same, we see convenience matter. So I think you and others follow the competition between the IL-23 classes.
We see drugs that are both delivered Q8W, one as an on-body pump, one as an auto-injector. The auto-injector wins by a fair margin. Similar safety and efficacy, but the auto-injector wins. So when we look at the profile of our combination therapies, having long-acting co-formulatable versions of both of these at high concentrations, we think we're uniquely able to get these into auto-injectors and deliver them subcutaneously, infrequently, and conveniently. Others who didn't start at the same place we did, with long-acting versions that we designed for co-formulations from the outset, you see a lot of combinations that are more combinations of convenience, basically combining what they had on their shelf at the same time. Things being repurposed from other indications, not designed for IBD, drugs with different dosing intervals.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
